TCM
VIR icon

Teza Capital Management’s Vir Biotechnology VIR Stock Holding History

Teza Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,277
Closed -$66.6K – 481
2025
Q1 		$66.6K Sell
10,277
-1,509
-13% -$13.4K 0.03% 395
2024
Q4 		$86.5K Sell
11,786
-2,066
-15% -$16.3K 0.01% 458
2024
Q3 		$104K Sell
13,852
-938
-6% -$8.15K 0.01% 566
2024
Q2 		$132K Sell
14,790
-2,195
-13% -$21.1K 0.02% 545
2024
Q1 		$172K Buy
+16,985
New +$173K 0.02% 529
2023
Q4 		– Sell
-23,022
Closed -$216K – 769
2023
Q3 		$216K Buy
+23,022
New +$328K 0.04% 513

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Teza Capital Management's VIR Position: Q2 2025 in Review

Teza Capital Management sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 10,277 shares — an estimated $66.6K sold.

Teza Capital Management first reported a position in VIR in Q3 2023 and held it in 6 quarters. The position peaked at $216K in Q3 2023. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Teza Capital Management reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Teza Capital Management sold 10,277 Vir Biotechnology shares in Q2 2025, an estimated $66.6K.
  • Teza Capital Management first reported a position in Vir Biotechnology in Q3 2023 and held it in 6 quarters.
  • Teza Capital Management's Vir Biotechnology position peaked at $216K in Q3 2023.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.